Laboratoires Thea acquires Mydriasert ophthalmic insert from Carl Zeiss Meditec

3 September 2010

Clermont-Ferrand, France-based Laboratoires Thea, a leading independent ophthalmic group in Europe, says it has completed its innovative product range with the acquisition of Mydriasert, the first mydriatic ophthalmic insert, from Carl Zeiss Meditec. Financial terms were not disclosed.

Mydriasert is indicated for dilated fundus examination (DFE) or cataract surgery, the most widely implemented surgical procedure. Regarding cataract surgery, the market represents close to 300 000 procedures in the UK and Ireland and 3 million in Europe each year.

"This acquisition represents a significant addition to our product range and is completely in line with our strategy to become a leading provider of ophthalmic products. Our goal is to meet the needs of ophthalmologists in all major therapeutic classes so that we can be their daily partners, whatever their type of practice, and notably in ocular surgery," according to Laboratoires Thea chief operating officer Jean-Frederic Chibret.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK